In my last article on Gadolinium based contrast agents (GBCAs), I discussed some of the side effects of these injections, which are administered to patients during a Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA). While GBCAs have started to draw attention in the pharmaceutical products liability legal realm, they have … [Read more...]
Gadolinium Deposition Disease can Result from use of Contrast Agents During MRI & MRA Procedures
What are Gadolinium-Based Contrast Agents (GBCAs)? GBCAs are substances that are injected into patients during Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) in order to produce clearer radiology images. Here is a list of GBCAs that are currently approved by the FDA: Ablavar Dotarem Eovist Gadavist … [Read more...]
FDA And MHRA Actions For Gadolinium-Containing Contrast Agents Differ
There is a difference between the United States FDA and the United Kingdom MHRA in terms of the regulatory actions being taken with respect gadolinium-based contrast agents (GBCAs). The drug safety issue is that low levels of gadolinium can be retained in the brain and other tissuesfor months to years after the administration of these drugs for … [Read more...]
MRI Drugs Magnevist, Omniscan, And OptiMARK Off The Market In Europe
The European Medicines Agency (EMA) recently announced it is taking regulatory action on certain magnetic resonance imaging (MRI) contrast drugs containing gadolinium a couple of months after the U.S. Food and Drug Administration (FDA) decided otherwise. We start with the timeline of events giving rise to the EMA's suspension of the MRI drugs … [Read more...]